Different HLA-DQ are Positively and Negatively Associated in Swedish Patients with Myasthenia Gravis

References

• Conti-Troconi B. M., McLane K. E., Raftery M. A., Grando S. A., Pia Protti M. The nicotinic acetycholine receptor: structure and autoimmune pathology. Crit. Rev. Biochem. Mol. Biol. 1994; 29: 69–123
   PubMed Web of Science ®Google Scholar
• Willcox N. Myasthenia gravis. Curr. Op. Immunol. 1993; 5: 910–917
   PubMed Web of Science ®Google Scholar
• Drachman D. B. Myasthenia gravis. N Eng. J. Med. 1994; 330: 1797–1810
   PubMed Web of Science ®Google Scholar
• Hohfeld R., Wekerle H. The role of the thymus in myasthenia gravis. Adv. Neuroimmunol. 1994; 4: 373–386
   PubMedGoogle Scholar
• Tournier-Lasserve E., Bach J.-F. The immunogenetics of myasthenia gravis, multiple sclerosis and their animal models. J. Neuroimmunol. 1993; 47: 103–114
   PubMed Web of Science ®Google Scholar
• Kaul R., Shenoy M., Christadoss P. The role of major histocompatibility complex genes in myasthenia gravis and experimental autoimmune myasthenia gravis pathogenesis. Adv. Neuroimmunol. 1994; 4: 387–402
   PubMedGoogle Scholar
• Pirskanen R., Tiilikainen A., Hokkanen E. Histocompatibility HL-A antigens associated with myasthenia gravis. A preliminary report. Ann. Clin. Res. 1972; 4: 304–306
   PubMedGoogle Scholar
• Van den Berg-Loonen E. M., Nijenhuis L. E., Engelfriet C. P., Feltkamp T. E.W., van Rossum A. L., Oosterhusi H. J.G.H. Segregation of HLA haplotypes in 100 families with a myasthenia gravis patient. J. Immunogenet. 1977; 4: 331–340
   PubMedGoogle Scholar
• Kaakinen A., Pirskanen R., Tiikanen A. LD antigens associated with HL-A8 and myasthenia gravis. Tissue Antigens 1915; 6: 175–182
   Google Scholar
• Möller E., Hammarström L., Smith E., Matell G. HL-A8 and LD-8a in patients with myasthenia gravis. Tissue Antigens 1976; 7: 39–44
   PubMedGoogle Scholar
• Dawkins R. L., Christiansen F. T., Kay P. H., Garlepp M., McCluskey J., Hollingsworth P. N., Zilko P. J. Disease associations with complotypes, supratypes and haplotypes. Immunol. Rev. 1983; 70: 5–22
   PubMed Web of Science ®Google Scholar
• Christiansen F. T., Pollack M. S., Garlepp M. J., Dawkins R. L. Myasthenia gravis and HLA antigens in American Blacks and other races. J. Neuroimmunol. 1984; 7: 121–129
   PubMed Web of Science ®Google Scholar
• Chen W.-H., Chiu H.-C., Hseih R.-P. Association of HLA-Bw46DR9 combination with juvenile myasthenia gravis in Chinese. J. Neurol. Neurosurg. Psychiatry 1993; 56: 382–385
   PubMed Web of Science ®Google Scholar
• Chan S. H., Tan C. B., Lin Y. N., Wee G. B., Degli-Eposti M. A., Dawkins R. L. HLA and Singaporean Chinese myasthenia gravis. Int. Arch. Allergy Immunol. 1993; 101: 119–125
   PubMed Web of Science ®Google Scholar
• Horiki T., Inoko H., Moriuchi J., Ichikawa Y., Arimori S. Combinations of HLA-DP1 and DQB1 alleles determine susceptibility to early-onset myasthenia gravis in Japan. Autoimmunity 1994; 19: 49–54
   PubMed Web of Science ®Google Scholar
• Matsuki K., Juji T., Tokunaga K., Takamizawa M., Maeda H., Soda M., Nomura Y., Segawa M. HLA antigens in Japanese patients with myasthenia gravis. J. Clin. Invest. 1990; 86: 392–399
   PubMed Web of Science ®Google Scholar
• Mehra N. K., Ahuja G. K., Taneja V., Vaidya M. C. HLA Antigens and myasthenia gravis in north India. J. Neurol. Neurosurg. Psychiatry 1983; 46: 361–364
   PubMed Web of Science ®Google Scholar
• Barton E. N., Smikle M., Morgan O. S.C. Myasthenia gravis and HLA phenotypes in Jamaicans. South. Med. J. 1992; 85: 904–906
   PubMed Web of Science ®Google Scholar
• Compston D. A.S., Vincent A., Newsom-Davis J., Batchelor J. R. Clinical, pathological, HLA antigen and immunological evidence for disease heterogeneity in myasthenia gravis. Brain 1980; 103: 579–601
   PubMed Web of Science ®Google Scholar
• Vieira M. L., Caillat-Zucman S., Gajdos P., Cohen-Kaminsky S., Casteur A., Bach J.-F. Identification by genomic typing of non-DR3 HLA class II genes associated with myasthenia gravis. J. Neuroimmunol. 1993; 47: 115–122
   PubMed Web of Science ®Google Scholar
• Carlsson B., Wallin J., Pirskanen R., Matell G., Smith C LE. Different HLA DR-DQ associations in subgroups of idiopathic myasthenia gravis. Immunogenetics 1990; 31: 285–290
   PubMed Web of Science ®Google Scholar
• Spurkland A., Gilhus N. E., Rønningen K. S., Aarli J. A., Vartdal F. Myasthenia gravis patients with thymus hyperplasia and myasthenia gravis patients with thymoma display different HLA associations. Tissue Antigens 1991; 37: 90–93
   PubMed Web of Science ®Google Scholar
• Khalil I., Berrih-Aknin S., Lepage V., Loste M.-N., Gajdos P., Hors J., Charron D., Degos L. Trans-encoded DQαβ heterodimers confer susceptibility to myasthenia gravis disease. C. R. Acad. Sci. Paris 1993; 316: 652–660
   PubMed Web of Science ®Google Scholar
• Bell J., Smoot S., Newby C., Toyka K., Rassenti L., Smith K., Hohlfeld R., McDevitt H. O., Steinman L. HLA-DQ beta-chain polymorphism linked to myasthenia gravis. Lancet 1986; 1: 1058–1060
   PubMed Web of Science ®Google Scholar
• Christadoss P., Lindstrom J. M., Melvold R. W., Talal N. Mutation at I-Aβ chain prevents experimental autoimmune myasthenia gravis. Immunogenetics 1985; 31: 241–244
   Google Scholar
• Oosterhuis H. J.G.H. Studies in myasthenia gravis. J. Neurol. Sci. 1964; 1: 512–546
   PubMed Web of Science ®Google Scholar
• Sanjeevi C. B., Seshiah V., Möller E., Olerup O. Different genetic backgrounds for malnutrition-related diabetes and Type 1 (insulin-dependent) diabetes mellitus in South Indians. Diabetologia 1992; 35: 283–286
   PubMed Web of Science ®Google Scholar
• Woolf B. On estimating the relation between blood group and disease. Ann. Hum. Genet. 1955; 19: 251–253
   PubMed Web of Science ®Google Scholar
• Waldor M. K., Sriram S., McDevitt H. O., Steinman L. In vivo therapy with monoclonal anti-I-A antibody suppresses immune response to AChR. Proc. Natl. Acad. Sci. USA 1983; 80: 2713–2717
   PubMed Web of Science ®Google Scholar
• Bellone M., Ostllie N., Lei S., Wu X. D., Conti-Troconi B. M. The I-Abm12 mutation, which confers resistance to experimental autoimmune myasthenia gravis, drastically affects the epitope repertoire of murine CD4 + cells sensitized to nicotinic acetylcholine receptor. J. Immunol. 1991; 147: 1484–1491
   PubMed Web of Science ®Google Scholar
• McIntyre K., Seidman J. G. Nucleotide sequence of mutant I-Aβbm12 gene is evidence for genetic exchange between mouse immune reponse genes. Nature 1984; 308: 551–553
   PubMed Web of Science ®Google Scholar
• Morita K., Moriuchi J., Inoko H., Tsuji K., Arimori S. HLA class II antigens and DNA restriction fragment length polymorphism in myasthenia gravis in Japan. Ann. Neurol. 1991; 29: 168–174
   PubMed Web of Science ®Google Scholar
• Degli-Esposti M. A., Andreas A., Christiansen F. T., Schalke B., Albert E., Dawkins R. L. An approach to the localization of the susceptibility genes for general myasthenia gravis by mapping recombinant ancestral haplotypes. Immunogenetics 1992; 35: 355–364
   PubMed Web of Science ®Google Scholar
• Oksenberg J. R., Sherritt M., Begovich A. B., Erlich H. A., Bernard C. C., Cavalli-Sforza L. L., Steinman L. T-cell receptor Vα and Cα alleles associated with multiple sclerosis and myasthenia gravis. Proc. Natl. Acad. Sci. USA 1989; 86: 988–992
   PubMed Web of Science ®Google Scholar
• Mantegazza R., Oksenberg J. R., Baggi F., Antozzi C., Illeni M. T., Pellegris G., Cornelio F., Steinman L. Increased incidence of certain TCR and HLA genes associated with myasthenia gravis in Italians. J. Autoimmun. 1990; 3: 431–440
   PubMed Web of Science ®Google Scholar
• Grünewald J., Åhlberg R., Lefvert A.-K., Dersimonian H., Wigzell H., Janson C. H. Abnormal T-cell expansion and V-gene usage in myasthenia gravis patients. Scand. J. Immunol. 1991; 34: 161–168
   PubMed Web of Science ®Google Scholar
• Garchon H.-J., Djabiri F., Viard J.-P., Gajdos P., Bach J.-F. Involvement of human muscle acetylcholine receptor α-subunit gene (CHRNA) in susceptibility to myasthenia gravis. Proc. Natl. Acad. Sci. USA 1994; 91: 4668–4672
   PubMed Web of Science ®Google Scholar
• Vincent A. Aetiological factors in development of myasthenia gravis. Adv. Neuroimmunol. 1994; 4: 355–371
   PubMedGoogle Scholar
• Kockum I., Wassmuth R., Holmberg E., Michelsen B., Lernmark Å. HLA-DQ primarily confers protection and HLA-DR susceptibility in Type 1 (insulin-dependent) diabetes studied in population-based affected families and controls. Am. J. Hum. Genet. 1993; 53: 150–167
   PubMed Web of Science ®Google Scholar
• Sanjeevi C. B., Lybrand T. P., DeWeese C., Landin Olsson M., Kockum I., Dahlquist G., Sundkvist G., Stenger D., Lernmark Å. Polymorphic amino acid variations in HLA-DQ are associated with systematic physical property changes and occurence of insulin-dependent diabetes mellitus. Diabetes 1995; 1: 125–131
   Google Scholar